查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968532

濾泡刺激素市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Follicle Stimulating Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application (Infertility Treatment, Assisted Reproductive Application, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球濾泡刺激素市場預計將從 2025 年的 19.1 億美元成長到 2031 年的 26.9 億美元，複合年成長率達到 5.87%。

濾泡刺激素由腦下垂體前葉分泌，是一種重要的促性腺激素，它調節女性卵泡發育和男性精子生成。該市場的成長主要受不孕症上升和生育年齡延遲等文化趨勢的驅動，這兩種趨勢都導致人們對輔助生殖技術的依賴性增強。人口結構的變化也支撐了這一需求的激增，這些變化表明全球自然生育率正在下降。例如，美國生殖醫學會2025年發布的報告顯示，2024年全球平均生育率為每人2.2個嬰兒。

市場概覽
預測期 2027-2031
市場規模：2025年 19.1億美元
市場規模：2031年 26.9億美元
複合年成長率：2026-2031年 5.87%
成長最快的細分市場 不孕症治療
最大的市場 北美洲

儘管需求成長帶來利好，但市場仍面臨許多挑戰。這些挑戰主要源自於不孕症治療費用極高，以及許多地區缺乏足夠的保險保障。這些經濟障礙限制了患者獲得必要治療的機會，並造成不同經濟區域間治療機會的顯著不平等，阻礙了市場的潛在成長。

市場促進因素

輔助生殖技術（ART）的日益普及是市場成長的主要驅動力，因為諸如體外受精（IVF）等手術嚴重依賴外源性促性腺激素來促進控制性卵巢過度刺激。在這些臨床情況下，濾泡刺激素對於募集多個卵泡至關重要，從而最大限度地提高卵子回收率，增加懷孕數率。隨著全球治療數量的增加，這種醫療需求也帶來了對藥物的穩定需求。特別是，根據英國人類受精與胚胎管理局（HFEA）2024年6月發布的數據，2022年英國的IVF週期數約為77,000個，比疫情前增加了11%。

同時，生育年齡延遲的社會趨勢進一步加劇了對這類醫療干預的需求，因為母親年齡的成長與卵巢儲備下降和卵子品質惡化密切相關。這種族群結構的變化使得使用高劑量促卵泡激素（FSH）通訊協定對於確保成功懷孕至關重要。東亞地區的數據也印證了這項需求的迫切性。根據韓國統計廳2024年8月發布的報告，2023年韓國的總合生育率驟降至歷史新低，僅每位女性0.72個孩子。因此，這項需求催生了強勁的商業環境。歐加農公司2024年的報告顯示，其女性健康業務部門第三季的營收成長了5%，這主要得益於生育治療產品的強勁銷售。

市場挑戰

高昂的生育治療費用是全球濾泡刺激素）市場成長的主要障礙。由於濾泡刺激素是輔助生殖技術中的關鍵藥物成分，這些治療的高昂費用限制了只有經濟條件充足的人才能獲得治療機會。這種經濟障礙導致全球治療週期數量下降，直接抑制了對該激素的需求，並限制了整體市場收入。在醫療保健資源匱乏的地區，這種經濟負擔尤其沉重，迫使患者自費承擔費用，並常常導致較高的治療中斷率。

此外，缺乏全面的保險覆蓋加劇了這個問題，擴大了臨床需求與醫療服務取得之間的差距。如果沒有經濟支持，多次治療週期的累積費用對大多數人來說將難以承受，從而有效地限制了市場覆蓋範圍。根據美國生殖醫學會2024年報告，美國一次體外受精（IVF）週期的平均費用在12,000美元至15,000美元之間。如此沉重的經濟負擔凸顯了阻礙IVF普及和市場成長的經濟障礙的嚴重性。

市場趨勢

生物相似藥FSH療法的引進和商業化正在從根本上改變競爭格局，為傳統的重組產品提供更經濟實惠的替代方案。隨著關鍵原廠生物製藥專利的到期，生物相似藥生產商正積極利用低價策略擴大市場佔有率，迫使現有公司大幅降價以維持其處方量。價格下降一方面給傳統品牌的獲利能力帶來壓力，另一方面透過降低治療週期成本，提高了生育治療的可近性。例如，歐加農公司在2025年2月發布的報告中揭露，其旗艦生育產品Follistim AQ在2024年全年的全球銷售額下降了10%。這一下降主要歸因於競爭對手的降價和日益激烈的全球競爭。

同時，人工智慧（AI）在精準給藥策略中的應用，正透過實現高度個人化的治療通訊協定，徹底改變卵巢刺激療法。醫療專業人員擴大使用基於人工智慧的演算法來評估患者特異性生物標記，例如基準荷爾蒙水平和卵泡計數，並確定每個週期的最佳促卵泡激素（FSH）劑量。這項技術進步透過摒棄統一的標準化給藥方法，降低了卵巢過度刺激症候群的風險，並提高了取卵效率。根據《IVF-Worldwide》雜誌2025年5月刊報道，到2025年，生育專家在精準給藥和胚胎選擇等工作中使用人工智慧工具的比例將成長至約29.2%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球濾泡刺激素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（重組FSH、尿源性FSH）
    • 依應用領域（不孕症治療、輔助生殖技術（ART）、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美濾泡刺激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲濾泡刺激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區濾泡刺激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲濾泡刺激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲濾泡刺激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球濾泡刺激素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck KgAa
  • Creative BioMart inc.
  • Midas Pharma GmbH
  • Genpharm Services
  • Livzon Pharmaceutical Group Inc
  • Shanghai Techwell Biopharmaceutical Co., Ltd
  • Medix Biochemica USA Inc.
  • Biogenix Inc.Pvt.Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19204

The Global Follicle Stimulating Hormone Market is projected to expand from USD 1.91 Billion in 2025 to USD 2.69 Billion by 2031, achieving a compound annual growth rate of 5.87%. Produced by the anterior pituitary gland, follicle stimulating hormone is a vital gonadotropin that orchestrates the development of ovarian follicles in women and regulates spermatogenesis in men. The market is primarily propelled by rising infertility rates and a cultural trend toward postponing childbirth, both of which increase the reliance on assisted reproductive technologies. This surge in demand is corroborated by demographic shifts showing a global reduction in natural birth rates; for instance, the American Society for Reproductive Medicine noted in 2025 that the average global fertility rate stood at 2.2 births per woman in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.91 Billion
Market Size 2031USD 2.69 Billion
CAGR 2026-20315.87%
Fastest Growing SegmentInfertility Treatment
Largest MarketNorth America

Despite these favorable demand drivers, the market encounters significant obstacles stemming from the exorbitant costs of fertility treatments and the scarcity of adequate insurance coverage in numerous areas. These financial hurdles limit patient access to essential therapies and generate marked inequalities in treatment availability across various economic regions, ultimately retarding the market's potential growth.

Market Driver

The rising adoption of Assisted Reproductive Technologies (ART) acts as a primary engine for market growth, given that procedures like In Vitro Fertilization (IVF) depend heavily on exogenous gonadotropins to stimulate controlled ovarian hyperstimulation. In these clinical scenarios, Follicle Stimulating Hormone is crucial for recruiting multiple ovarian follicles, which maximizes the harvest of viable oocytes and enhances the likelihood of conception. This medical requirement creates a steady demand for pharmaceuticals as treatment volumes increase worldwide; notably, the Human Fertilisation and Embryology Authority reported in June 2024 that IVF cycles in the UK rose to approximately 77,000 in 2022, representing an 11% increase over pre-pandemic figures.

Concurrently, the societal trend toward delayed childbearing intensifies the need for these medical interventions, as increased maternal age is associated with lower ovarian reserves and compromised oocyte quality. This demographic shift necessitates the use of higher-dosage FSH protocols to secure successful pregnancy results. The severity of this need is highlighted by data from East Asia, where Statistics Korea reported in August 2024 that the total fertility rate plummeted to a historic low of 0.72 children per woman in 2023. Consequently, this demand fosters a strong commercial landscape, illustrated by Organon's 2024 report indicating a 5% revenue increase in its Women's Health segment during the third quarter, largely attributed to the robust sales of fertility products.

Market Challenge

The high expenses linked to fertility treatments present a major hurdle that constrains the growth of the Global Follicle Stimulating Hormone Market. As follicle stimulating hormone is a key pharmaceutical ingredient in assisted reproductive technology regimens, the steep price of these procedures restricts the potential patient population to those with substantial financial resources. This economic exclusion results in fewer treatment cycles being initiated worldwide, which directly suppresses demand for the hormone and limits overall market revenue. The financial strain is especially severe in areas without strong public healthcare support, compelling patients to cover costs out-of-pocket and frequently leading to high rates of treatment discontinuation.

Moreover, the absence of comprehensive insurance coverage worsens this issue by expanding the divide between clinical necessity and access to care. Lacking financial aid, the accumulated costs of required multiple cycles become unaffordable for most people, effectively limiting market reach. As reported by the American Society for Reproductive Medicine in 2024, the average cost for a single in vitro fertilization cycle in the United States fell between $12,000 and $15,000. This significant financial demand underscores the gravity of the economic barriers that hinder widespread usage and impede the market's growth trajectory.

Market Trends

The introduction and commercialization of biosimilar FSH therapies are fundamentally transforming the competitive environment by offering more affordable alternatives to traditional recombinant products. As patents on leading originator biologics expire, manufacturers of biosimilars are aggressively gaining market share through lower pricing, forcing established companies to offer steeper discounts to keep their formulary spots. This trend of price erosion is cutting into the revenue of legacy brands while simultaneously making fertility treatments more accessible by reducing cycle costs. For example, Organon revealed in its February 2025 report that global sales of its flagship fertility product, Follistim AQ, fell by 10% throughout 2024, a decline largely blamed on competitive discounting and heightened global rivalry.

At the same time, the incorporation of artificial intelligence into precision dosing strategies is revolutionizing ovarian stimulation by facilitating highly customized treatment protocols. Medical professionals are increasingly utilizing AI-based algorithms to evaluate patient-specific biomarkers, such as baseline hormone levels and follicle counts, to determine the ideal FSH dosage for each cycle. This technological advancement reduces the risk of ovarian hyperstimulation syndrome and enhances oocyte retrieval efficiency by abandoning generic, standardized dosing methods. According to a May 2025 article in the Journal of IVF-Worldwide, the usage of AI tools by fertility specialists for tasks like precision dosing and embryo selection increased to approximately 29.2% in 2025.

Key Market Players

  • Merck KgAa
  • Creative BioMart inc.
  • Midas Pharma GmbH
  • Genpharm Services
  • Livzon Pharmaceutical Group Inc
  • Shanghai Techwell Biopharmaceutical Co., Ltd
  • Medix Biochemica USA Inc.
  • Biogenix Inc.Pvt.Ltd.

Report Scope

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicle Stimulating Hormone Market, By Type

  • Recombinant FSH
  • Urinary FSH

Follicle Stimulating Hormone Market, By Application

  • Infertility Treatment
  • Assisted Reproductive Application (ART)
  • Others

Follicle Stimulating Hormone Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicle Stimulating Hormone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Recombinant FSH, Urinary FSH)
    • 5.2.2. By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Follicle Stimulating Hormone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Follicle Stimulating Hormone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Follicle Stimulating Hormone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Follicle Stimulating Hormone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Follicle Stimulating Hormone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Follicle Stimulating Hormone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Follicle Stimulating Hormone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Follicle Stimulating Hormone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Follicle Stimulating Hormone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Follicle Stimulating Hormone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Follicle Stimulating Hormone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Follicle Stimulating Hormone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Follicle Stimulating Hormone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Follicle Stimulating Hormone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Follicle Stimulating Hormone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Follicle Stimulating Hormone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Follicle Stimulating Hormone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Follicle Stimulating Hormone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Follicle Stimulating Hormone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Follicle Stimulating Hormone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Follicle Stimulating Hormone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Follicle Stimulating Hormone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Follicle Stimulating Hormone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Follicle Stimulating Hormone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Follicle Stimulating Hormone Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KgAa
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Creative BioMart inc.
  • 15.3. Midas Pharma GmbH
  • 15.4. Genpharm Services
  • 15.5. Livzon Pharmaceutical Group Inc
  • 15.6. Shanghai Techwell Biopharmaceutical Co., Ltd
  • 15.7. Medix Biochemica USA Inc.
  • 15.8. Biogenix Inc.Pvt.Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer